Viralgen
- Company typePrivate
- Founded2017
- HeadquartersSan Sebastian, Spain
- Headcount251–500
- GTM typeB2B
- OfferingServices
Viralgen firmographics
Firmographics- Name
- Viralgen
- Legal name
- Viralgen
- Website
- https://viralgenvc.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Viralgen industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where Viralgen is headquartered
LocationHeadquarters
- HQ city
- San Sebastian
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Viralgen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services (CDMO): Viralgen generates revenue through providing end-to-end AAV gene therapy manufacturing services including process development, early and late phase clinical production, and commercial manufacturing. Services are delivered through fixed-cost packages and all-inclusive pricing models for pharmaceutical and biotech clients.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Viralgen product offering
Product offeringCore offering
Viralgen is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end cGMP manufacturing of adeno-associated virus (AAV) vectors for gene therapy developers. Its offering is anchored by the proprietary Aava™ Platform built on the AskBio Pro10™ HEK293 suspension cell line, delivering scalable production across all AAV serotypes from 100ml to 2,000L, supported by integrated QC/release testing and regulatory expertise for IND, IMPD, BLA and CMC filings.
Product overview
Viralgen is a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in AAV-based gene therapy manufacturing. The company's offering centers on the Aava™ Platform, a proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line, which delivers high-yield scalable production across all AAV serotypes from 100ml to 2,000L. Viralgen provides end-to-end services spanning Process Development (construct optimization and platform fit), Early Phase Production (feasibility studies and early clinical material), Late Phase Production (large-scale clinical and commercial manufacturing), and integrated QC/release support with over 85% of methods performed in-house, plus globally compliant regulatory support for CMC filings. The company operates the world's largest AAV-dedicated facility (343,255 sq ft) in San Sebastián, Spain.
Differentiator
Problem solved
Functional benefit
Brands
- Aava™ Platform: Viralgen's proprietary manufacturing platform built on the AskBio Pro10™ suspension cell line for high-yield scalable AAV manufacturing across all serotypes.
Products and services
- Aava™ Platform Proprietary AAV manufacturing platform built upon the AskBio Pro10™ HEK293 suspension cell line, enabling high-yield scalable manufacturing across all AAV serotypes from 100ml to 2,000L for gene therapy developers.
- Process Development Early-stage development services including construct optimization and platform fit assessment to guide gene therapy development decisions for pharmaceutical and biotech clients.
- Early Phase Production Clinical trial material production for early-phase studies, including small feasibility studies and GMP-compliant manufacturing for gene therapy programs.
- Late Phase Production Late-stage clinical and commercial manufacturing services including large-scale production, purification, and fill-finish across broad format ranges for gene therapy programs.
- Plasmid DNA Production Plasmid DNA production provided as part of end-to-end AAV manufacturing support, from construct optimization through large-scale production.
Quantifiable outcome
- 100% success rate for IND/IMPD dossiers submitted
- +4 more outcomes
Companies that use Viralgen
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Viralgen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Viralgen partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- MyrtellecoreMyrtelle presented clinical trial data for its MYR-101 gene therapy program for Canavan disease at ASGCT 2026, with CEO Adrian Stecyk speaking at a Viralgen-hosted symposium. Viralgen provides manufacturing support for Myrtelle's gene therapy program, which holds an exclusive worldwide licensing agreement with Pfizer Inc. and is participating in the FDA START Pilot Program.
- Elaaj BiocoreViralgen partnered with Elaaj Bio to advance ELJ-101, a preclinical-stage investigational gene therapy for CDKL5 Deficiency Disorder (CDD), a rare pediatric neurological condition. Viralgen provides AAV manufacturing expertise including process development, optimization, and scale-up activities. Initial development work has demonstrated technical feasibility, with the collaboration aiming to initiate the first clinical trial in early 2027. Elaaj Bio is a wholly-owned subsidiary of the UK-based Loulou Foundation.
- AskBiocoreAskBio (parent company) introduced its proprietary commercially ready manufacturing process to supply ametefgene parvec (AB-1005) for the REGENERATE-PD Phase II clinical trial for Parkinson's disease, with drug product manufactured at Viralgen's commercial facility in Spain using next-generation large-scale suspension process. The trial is enrolling across Germany, Poland, UK, and US.
- Apertura Gene TherapycoreViralgen and Apertura Gene Therapy announced a strategic manufacturing collaboration to produce TfR1 CapX, a novel AAV capsid designed to cross the blood-brain barrier for treating central nervous system diseases. The partnership enables Apertura's licensees to access TfR1 CapX plasmids through Viralgen's integrated AAV manufacturing platform, with multiple partner programs expected to advance into clinical trials. Viralgen has already scaled up manufacturing and is ready to support clinical development.
- Bayer AGcoreBayer AG, through its subsidiary Viralgen, is developing cell and gene therapies (CGT) aimed at treating diseases such as Parkinson's, oncology, cardiovascular, and rare conditions. Bayer acquired AskBio (Viralgen's parent company) in fall 2020 for up to $4 billion and is expanding its pipeline and manufacturing capacity.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Viralgen competitors and assessment
Company assessmentDirect peers
- Yposkesi: Yposkesi is a European AAV and lentiviral vector CDMO located in France, serving gene therapy developers with cGMP manufacturing. Its AAV focus and European footprint make it a direct competitor to Viralgen in the EMEA region.
- Biovian: Biovian is a European CDMO offering AAV, lentiviral, and other viral vector manufacturing services. It is a direct peer in the AAV gene therapy manufacturing space, particularly for European biotech customers.
- Forge Biologics: Forge Biologics is a US-based CDMO specializing in AAV and lentiviral vector manufacturing with scalable cGMP production. It is one of the most directly comparable AAV-focused CDMOs to Viralgen, competing for the same gene therapy developer customers.
Broad incumbents
- Catalent (Novo Holdings): Catalent, recently acquired by Novo Holdings, offers viral vector manufacturing including AAV alongside a broad biologics CDMO portfolio. It is a major incumbent competitor for gene therapy manufacturing services.
- AGC Biologics: AGC Biologics provides viral vector and cell therapy CDMO services as part of its broader biologics manufacturing offerings. It is a relevant incumbent peer for AAV gene therapy manufacturing contracts.
- Lonza (Cell & Gene Technologies): Lonza is one of the largest global CDMOs with a substantial viral vector and cell therapy manufacturing offering across multiple sites. It competes with Viralgen for AAV gene therapy manufacturing contracts as part of a broader biologics portfolio.
- Charles River Laboratories (Viral Vector): Charles River Laboratories offers viral vector and gene therapy CDMO services including AAV manufacturing as part of its broader discovery and manufacturing portfolio. It is a relevant incumbent peer for gene therapy manufacturing.
- Thermo Fisher Scientific (Viral Vector Services): Thermo Fisher Scientific provides viral vector manufacturing services through its pharma services division as part of a massive global CDMO portfolio. It competes with Viralgen for AAV contracts through its Patheon and Brammer Bio operations.
Emerging players
- Genezen: Genezen is a US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene and cell therapy developers. It is an emerging specialist competitor with overlapping AAV capabilities and customer base.
- Centre for Breakthrough Medicines: Centre for Breakthrough Medicines is a US-based cell and gene therapy CDMO offering AAV and other viral vector manufacturing. It is an emerging player competing for similar gene therapy developer clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Viralgen social profiles
Digital presenceViralgen compliance and trust
Trust signalCompliance1 record
Viralgen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Viralgen leadership team
Management profileNumber of profiles
Viralgen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Viralgen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Viralgen
What does Viralgen do?
Viralgen is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end cGMP manufacturing of adeno-associated virus (AAV) vectors for gene therapy developers. Its offering is anchored by the proprietary Aava™ Platform built on the AskBio Pro10™ HEK293 suspension cell line, delivering scalable production across all AAV serotypes from 100ml to 2,000L, supported by integrated QC/release testing and regulatory expertise for IND, IMPD, BLA and CMC filings.
Is Viralgen a public or private company?
Viralgen is a private company. It is classified as corporate owned and is currently operating.
When was Viralgen founded?
Viralgen was founded in 2017. It employs 251 to 500 people.
Where is Viralgen based?
Viralgen is headquartered in San Sebastian, Spain, in the Europe region.
How does Viralgen make money?
One revenue line is on record: contract Development and Manufacturing Services (CDMO).
Who are Viralgen's main competitors?
Direct peers on record are Yposkesi, Biovian and Forge Biologics. Broad incumbents are Catalent (Novo Holdings), AGC Biologics, Lonza (Cell & Gene Technologies), Charles River Laboratories (Viral Vector) and Thermo Fisher Scientific (Viral Vector Services). Emerging players are Genezen and Centre for Breakthrough Medicines.
Does Viralgen have an API?
No public API is recorded for Viralgen.
What industry is Viralgen in?
Viralgen's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2836.